Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer

Author： Mukai Hirofumi   Takahashi Shunji   Nozawa Masahiro   Onozawa Yusuke   Miyazaki Jun   Ohno Keiji   Suzuki Kazuhiro  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.4, 2014-04, pp. : 703-710

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study

By Kamiya Naoto   Suzuki Hiroyoshi   Ueda Takeshi   Sato Naohide   Nakatsu Hiroomi   Mikami Kazuo   Sato Nobuo   Nomura Kazushi   Akakura Koichiro   Okano Tatsuya   Ooki Takemasa   Naya Yukio   Ota Sho   Masai Motoyuki   Ichikawa Tomohiko  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 157-164

Springer Publishing Company

Access to resources Recommend Favorite

Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients

By Kita Yuki   Shimizu Yosuke   Inoue Takahiro   Kamba Tomomi   Yoshimura Koji   Ogawa Osamu  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 718-723

Springer Publishing Company

Access to resources Recommend Favorite

Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

By Hatano Koji   Nishimura Kazuo   Nakai Yasutomo   Yoshida Takahiro   Sato Mototaka   Kawashima Atsunari   Mukai Masatoshi   Nagahara Akira   Uemura Motohide   Oka Daizo   Nakayama Masashi   Takayama Hitoshi   Shimizu Kiyonori   Meguro Norio   Tanigawa Tsuyoshi   Yamaguchi Seiji   Tsujimura Akira   Nonomura Norio  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 704-710

Springer Publishing Company

Access to resources Recommend Favorite

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

By Oudard Stephane  

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 497-506

Future Medicine

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite